Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

@article{Herrmann2016VascularTO,
  title={Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.},
  author={Joerg Herrmann and Eric H. Yang and Cezar Iliescu and Mehmet Cilingiroglu and Konstantinos Charitakis and Abdul Hakeem and Konstantinos Toutouzas and Massoud A. Leesar and Cindy Lee Grines and Konstantinos Marmagkiolis},
  journal={Circulation},
  year={2016},
  volume={133 13},
  pages={
          1272-89
        }
}
Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 187 references

Similar Papers

Loading similar papers…